Biomea Fusion Announces Participation at the H.C. Wainwright 2022 BioConnect Conference
Biomea Fusion (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, announced its participation at the H.C. Wainwright BioConnect Conference held from January 10-13, 2022. CEO Thomas Butler will provide a corporate update during a fireside chat. The company is focused on developing irreversible small molecules for treating genetically defined cancers and metabolic diseases, utilizing its proprietary FUSION™ discovery platform. This innovative approach aims to offer significant advantages in drug efficacy and patient outcomes.
- Participation in H.C. Wainwright BioConnect Conference enhances visibility among institutional investors.
- Focus on irreversible small molecules may lead to improved treatment outcomes for patients.
- None.
REDWOOD CITY, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference. The conference is being held on January 10-13, 2022, virtually.
Thomas Butler, Chief Executive Officer and Chairman of the Board of Biomea Fusion, will provide a corporate update during the fireside chat.
If you are an institutional investor, and would like to listen to the Company’s presentation, please click on the following link (www.hcwevents.com/bioconnect) to register for the conference. Additionally, a live audio webcast of the fireside chat can be accessed at https://investors.biomeafusion.com/ and will be available for 90 days following the presentation.
About Biomea Fusion
Biomea Fusion is a biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. An irreversible small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. The company is utilizing its proprietary FUSION™ discovery platform to advance a pipeline of irreversible-binding therapeutic agents against key oncogenic drivers of cancer and metabolic diseases. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing irreversible small molecules in order to maximize the clinical benefit when treating various cancers and metabolic diseases.
Contact:
Van Sandwick
Director, Investor Relations & Corporate Development
vsandwick@biomeafusion.com
(650) 460-7759
FAQ
What is Biomea Fusion's focus in drug development?
When is the H.C. Wainwright BioConnect Conference?
Who will represent Biomea Fusion at the conference?
How can I access the live webcast of Biomea Fusion's presentation?
